Company Overview

Silence Therapeutics plc is a biotechnology company focused on the discovery and development of RNA interference (RNAi)–based therapeutics. The company operates within the biopharmaceutical and genetic medicines industries, with a strategic emphasis on diseases where long‑term gene silencing can provide durable clinical benefit. Its core capability is the development of small interfering RNA (siRNA) medicines designed to selectively silence disease‑associated genes.

The company’s primary value drivers are its wholly owned and partnered siRNA drug candidates built on its proprietary mRNAi GOLD™ platform, which is designed for targeted delivery to specific tissues, particularly the liver. Silence Therapeutics serves global pharmaceutical partners and specialty disease markets, positioning itself as a platform innovator rather than a fully integrated commercial-stage drug company. Founded in the 1990s and originally known as Ribopharma, the company evolved through multiple restructurings and technology shifts, ultimately rebranding as Silence Therapeutics plc and focusing exclusively on next‑generation RNAi therapeutics.

Business Operations

Silence Therapeutics conducts operations primarily through its research and development segment, which encompasses target discovery, siRNA design, preclinical development, and early‑stage clinical trials. Revenue generation has historically been driven by strategic collaborations, licensing agreements, upfront payments, and milestone-based payments, rather than product sales, as the company does not yet have commercialized therapies.

The company operates internationally, with R&D activities in the United Kingdom and Germany, and corporate functions aligned to its status as a UK‑incorporated public company listed in the United States. Silence controls its proprietary mRNAi GOLD™ delivery technology and maintains a portfolio of internally developed and partnered assets. It has entered into major collaborations with large pharmaceutical companies and regional partners, while retaining select programs as wholly owned assets for potential late‑stage value creation.

Strategic Position & Investments

Silence Therapeutics’ strategy centers on advancing a focused pipeline of liver‑targeted and genetically defined RNAi therapeutics while leveraging partnerships to fund development and reduce capital risk. Growth initiatives include advancing lead clinical candidates, expanding its target discovery engine, and applying its delivery technology to new therapeutic areas such as cardiovascular, hematologic, and metabolic diseases.

Major investments have included the advancement and out‑licensing of SLN360 (also known as zerlasiran) for lipoprotein(a)–related cardiovascular risk and SLN124 for iron‑overload disorders. The company has established notable partnerships, including global and regional licensing arrangements with large pharmaceutical companies, while maintaining full ownership of select early‑stage programs. Silence is not structured as a holding company and does not maintain a diversified investment portfolio outside its therapeutic pipeline.

Geographic Footprint

Silence Therapeutics is headquartered in London, United Kingdom, with significant research operations in Berlin, Germany. The company’s corporate structure reflects its UK incorporation, while its public equity is traded on U.S. capital markets, giving it access to international investors.

Operational and strategic influence extends across Europe and North America, primarily through clinical development activities, regulatory engagement, and pharmaceutical partnerships. While the company does not operate commercial manufacturing facilities, its partnered programs and licensing agreements provide indirect exposure to Asia‑Pacific and other international markets through collaborators’ development and commercialization efforts.

Leadership & Governance

Silence Therapeutics is led by an executive team with experience in RNA biology, drug development, and global pharmaceutical partnerships. The leadership philosophy emphasizes capital discipline, platform-driven innovation, and selective partnering to maximize long‑term shareholder value while advancing novel genetic medicines.

Key executives include:

• David R. M. – Chief Executive Officer (Data inconclusive based on available public sources regarding tenure details)
• Laura Wood – Chief Financial Officer
• Philippe Giese – Chief Scientific Officer
• Craig Tooman – Chief Business Officer

The company is governed by a board of directors that combines scientific, financial, and industry expertise, consistent with governance standards applicable to UK‑incorporated, U.S.‑listed life sciences companies.

Verification Requirements